data_2h95_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2h95 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.768 HD11 ' CG1' ' B' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.769 ' CG1' HD11 ' D' ' 26' ' ' LEU . 91.6 t -65.49 -40.13 87.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.034 -1.041 . . . . 0.0 109.631 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.439 ' O ' ' OG ' ' A' ' 31' ' ' SER . 66.1 t -64.77 -46.51 91.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.416 -0.803 . . . . 0.0 108.949 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.22 -49.79 63.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.824 . . . . 0.0 109.832 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.074 -1.016 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.562 ' O ' HG13 ' A' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.624 ' O ' ' HB3' ' A' ' 37' ' ' HIS . 65.1 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.902 ' O ' ' HG ' ' A' ' 38' ' ' LEU . . . -63.07 -42.55 99.55 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.562 HG13 ' O ' ' A' ' 31' ' ' SER . 70.6 mt -62.88 -63.69 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.091 -1.24 . . . . 0.0 109.567 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.611 ' O ' ' HG ' ' A' ' 40' ' ' LEU . 47.0 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.624 ' HB3' ' O ' ' A' ' 33' ' ' ILE . 6.9 t-160 -61.5 -41.51 97.4 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.623 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.902 ' HG ' ' O ' ' A' ' 34' ' ' GLY . 88.0 mt -68.53 -39.57 81.1 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.018 -1.051 . . . . 0.0 109.912 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.405 HG13 ' O ' ' A' ' 35' ' ' ILE . 95.1 mt -60.54 -46.81 94.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.497 -0.752 . . . . 0.0 109.186 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.611 ' HG ' ' O ' ' A' ' 36' ' ' LEU . 68.2 mt -55.28 -36.95 66.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.346 -0.846 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -64.93 -44.59 88.97 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.602 -1.311 . . . . 0.0 109.74 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 44.3 mt -58.51 -39.71 76.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.037 -1.039 . . . . 0.0 109.71 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.759 HD11 ' CG1' ' C' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . 0.768 ' CG1' HD11 ' A' ' 26' ' ' LEU . 91.6 t -65.49 -40.12 87.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.002 -1.061 . . . . 0.0 109.634 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . 0.434 ' O ' ' OG ' ' B' ' 31' ' ' SER . 66.5 t -64.77 -46.51 91.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.416 -0.803 . . . . 0.0 108.949 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.22 -49.79 63.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.824 . . . . 0.0 109.832 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.074 -1.016 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' SER . . . . . 0.568 ' O ' HG13 ' B' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . 0.624 ' O ' ' HB3' ' B' ' 37' ' ' HIS . 65.1 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . 0.905 ' O ' ' HG ' ' B' ' 38' ' ' LEU . . . -63.07 -42.52 99.56 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . 0.568 HG13 ' O ' ' B' ' 31' ' ' SER . 70.7 mt -62.94 -63.66 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.082 -1.246 . . . . 0.0 109.556 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.616 ' O ' ' HG ' ' B' ' 40' ' ' LEU . 47.0 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.624 ' HB3' ' O ' ' B' ' 33' ' ' ILE . 6.9 t-160 -61.48 -41.5 97.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.228 -0.92 . . . . 0.0 109.683 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' LEU . . . . . 0.905 ' HG ' ' O ' ' B' ' 34' ' ' GLY . 87.9 mt -68.49 -39.66 81.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.018 -1.051 . . . . 0.0 109.895 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.404 HG13 ' O ' ' B' ' 35' ' ' ILE . 95.2 mt -60.47 -46.84 94.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.43 -0.794 . . . . 0.0 109.21 -179.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' LEU . . . . . 0.616 ' HG ' ' O ' ' B' ' 36' ' ' LEU . 68.2 mt -55.28 -36.95 66.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.346 -0.846 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -64.93 -44.59 88.97 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.602 -1.311 . . . . 0.0 109.74 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 44.0 mt -58.51 -39.71 76.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.037 -1.039 . . . . 0.0 109.71 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.753 HD11 ' CG1' ' D' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . 0.759 ' CG1' HD11 ' B' ' 26' ' ' LEU . 91.6 t -65.45 -40.13 87.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.034 -1.041 . . . . 0.0 109.619 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . 0.434 ' O ' ' OG ' ' C' ' 31' ' ' SER . 66.5 t -64.71 -46.58 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.49 -0.756 . . . . 0.0 108.981 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.21 -49.77 63.33 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.385 -0.822 . . . . 0.0 109.856 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.09 -1.007 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' SER . . . . . 0.561 ' O ' HG13 ' C' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . 0.623 ' O ' ' HB3' ' C' ' 37' ' ' HIS . 65.0 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.921 ' O ' ' HG ' ' C' ' 38' ' ' LEU . . . -63.05 -42.5 99.58 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . 0.561 HG13 ' O ' ' C' ' 31' ' ' SER . 70.7 mt -62.94 -63.66 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.082 -1.246 . . . . 0.0 109.556 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . 0.606 ' O ' ' HG ' ' C' ' 40' ' ' LEU . 46.9 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.623 ' HB3' ' O ' ' C' ' 33' ' ' ILE . 6.9 t-160 -61.5 -41.51 97.4 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.623 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' LEU . . . . . 0.921 ' HG ' ' O ' ' C' ' 34' ' ' GLY . 88.0 mt -68.53 -39.57 81.1 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.018 -1.051 . . . . 0.0 109.912 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.54 -46.81 94.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.453 -0.779 . . . . 0.0 109.186 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' LEU . . . . . 0.606 ' HG ' ' O ' ' C' ' 36' ' ' LEU . 68.2 mt -55.28 -36.99 66.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.6 m95 -64.84 -44.67 89.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.611 -1.305 . . . . 0.0 109.741 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 42' ' ' ILE . . . . . . . . . . . . . 44.6 mt -58.48 -39.72 76.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.696 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.769 HD11 ' CG1' ' A' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . 0.753 ' CG1' HD11 ' C' ' 26' ' ' LEU . 91.6 t -65.49 -40.13 87.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.034 -1.041 . . . . 0.0 109.631 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . 0.448 ' O ' ' OG ' ' D' ' 31' ' ' SER . 66.1 t -64.77 -46.51 91.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.416 -0.803 . . . . 0.0 108.949 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.22 -49.79 63.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.824 . . . . 0.0 109.832 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.074 -1.016 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' SER . . . . . 0.566 ' O ' HG13 ' D' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.624 ' O ' ' HB3' ' D' ' 37' ' ' HIS . 65.1 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . 0.906 ' O ' ' HG ' ' D' ' 38' ' ' LEU . . . -63.07 -42.52 99.56 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . 0.566 HG13 ' O ' ' D' ' 31' ' ' SER . 70.6 mt -62.94 -63.66 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.082 -1.246 . . . . 0.0 109.556 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . 0.608 ' O ' ' HG ' ' D' ' 40' ' ' LEU . 47.0 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.624 ' HB3' ' O ' ' D' ' 33' ' ' ILE . 6.9 t-160 -61.5 -41.51 97.4 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.623 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' LEU . . . . . 0.906 ' HG ' ' O ' ' D' ' 34' ' ' GLY . 88.0 mt -68.53 -39.57 81.1 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.018 -1.051 . . . . 0.0 109.912 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.54 -46.81 94.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.497 -0.752 . . . . 0.0 109.186 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' LEU . . . . . 0.608 ' HG ' ' O ' ' D' ' 36' ' ' LEU . 68.2 mt -55.28 -36.95 66.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.346 -0.846 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -64.93 -44.59 88.97 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.602 -1.311 . . . . 0.0 109.74 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 42' ' ' ILE . . . . . . . . . . . . . 44.0 mt -58.51 -39.71 76.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.037 -1.039 . . . . 0.0 109.71 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.526 ' CD1' HG12 ' B' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.535 HG12 ' CD1' ' D' ' 26' ' ' LEU . 91.6 t -65.49 -40.13 87.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.034 -1.041 . . . . 0.0 109.631 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.407 ' O ' ' OG ' ' A' ' 31' ' ' SER . 66.1 t -64.77 -46.51 91.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.416 -0.803 . . . . 0.0 108.949 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.22 -49.79 63.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.824 . . . . 0.0 109.832 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.074 -1.016 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.545 ' O ' HG13 ' A' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.649 ' O ' ' HB3' ' A' ' 37' ' ' HIS . 65.1 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.904 ' O ' ' HG ' ' A' ' 38' ' ' LEU . . . -63.07 -42.55 99.55 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.545 HG13 ' O ' ' A' ' 31' ' ' SER . 70.6 mt -62.88 -63.69 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.091 -1.24 . . . . 0.0 109.567 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.62 ' O ' ' HG ' ' A' ' 40' ' ' LEU . 47.0 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.649 ' HB3' ' O ' ' A' ' 33' ' ' ILE . 6.9 t-160 -61.5 -41.51 97.4 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.623 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.904 ' HG ' ' O ' ' A' ' 34' ' ' GLY . 88.0 mt -68.53 -39.57 81.1 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.018 -1.051 . . . . 0.0 109.912 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.54 -46.81 94.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.497 -0.752 . . . . 0.0 109.186 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.62 ' HG ' ' O ' ' A' ' 36' ' ' LEU . 68.2 mt -55.28 -36.95 66.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.346 -0.846 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -64.93 -44.59 88.97 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.602 -1.311 . . . . 0.0 109.74 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.411 ' H ' HG13 ' A' ' 42' ' ' ILE . 44.3 mt -58.51 -39.71 76.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.037 -1.039 . . . . 0.0 109.71 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.542 ' CD1' HG12 ' C' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.526 HG12 ' CD1' ' A' ' 26' ' ' LEU . 91.6 t -65.49 -40.12 87.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.002 -1.061 . . . . 0.0 109.634 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 66.5 t -64.77 -46.51 91.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.416 -0.803 . . . . 0.0 108.949 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.22 -49.79 63.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.824 . . . . 0.0 109.832 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.074 -1.016 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' SER . . . . . 0.554 ' O ' HG13 ' B' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' ILE . . . . . 0.648 ' O ' ' HB3' ' B' ' 37' ' ' HIS . 65.1 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' GLY . . . . . 0.91 ' O ' ' HG ' ' B' ' 38' ' ' LEU . . . -63.07 -42.52 99.56 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.554 HG13 ' O ' ' B' ' 31' ' ' SER . 70.7 mt -62.94 -63.66 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.082 -1.246 . . . . 0.0 109.556 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.626 ' O ' ' HG ' ' B' ' 40' ' ' LEU . 47.0 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.648 ' HB3' ' O ' ' B' ' 33' ' ' ILE . 6.9 t-160 -61.48 -41.5 97.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.228 -0.92 . . . . 0.0 109.683 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' LEU . . . . . 0.91 ' HG ' ' O ' ' B' ' 34' ' ' GLY . 87.9 mt -68.49 -39.66 81.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.018 -1.051 . . . . 0.0 109.895 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 95.2 mt -60.47 -46.84 94.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.43 -0.794 . . . . 0.0 109.21 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' LEU . . . . . 0.626 ' HG ' ' O ' ' B' ' 36' ' ' LEU . 68.2 mt -55.28 -36.95 66.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.346 -0.846 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -64.93 -44.59 88.97 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.602 -1.311 . . . . 0.0 109.74 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 44.0 mt -58.51 -39.71 76.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.037 -1.039 . . . . 0.0 109.71 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.543 ' CD1' HG12 ' D' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 27' ' ' VAL . . . . . 0.542 HG12 ' CD1' ' B' ' 26' ' ' LEU . 91.6 t -65.45 -40.13 87.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.034 -1.041 . . . . 0.0 109.619 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 28' ' ' VAL . . . . . 0.416 ' O ' ' OG ' ' C' ' 31' ' ' SER . 66.5 t -64.71 -46.58 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.49 -0.756 . . . . 0.0 108.981 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.21 -49.77 63.33 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.385 -0.822 . . . . 0.0 109.856 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.09 -1.007 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 31' ' ' SER . . . . . 0.543 ' O ' HG13 ' C' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 33' ' ' ILE . . . . . 0.645 ' O ' ' HB3' ' C' ' 37' ' ' HIS . 65.0 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.923 ' O ' ' HG ' ' C' ' 38' ' ' LEU . . . -63.05 -42.5 99.58 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 35' ' ' ILE . . . . . 0.543 HG13 ' O ' ' C' ' 31' ' ' SER . 70.7 mt -62.94 -63.66 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.082 -1.246 . . . . 0.0 109.556 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 36' ' ' LEU . . . . . 0.614 ' O ' ' HG ' ' C' ' 40' ' ' LEU . 46.9 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.645 ' HB3' ' O ' ' C' ' 33' ' ' ILE . 6.9 t-160 -61.5 -41.51 97.4 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.623 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 38' ' ' LEU . . . . . 0.923 ' HG ' ' O ' ' C' ' 34' ' ' GLY . 88.0 mt -68.53 -39.57 81.1 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.018 -1.051 . . . . 0.0 109.912 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.54 -46.81 94.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.453 -0.779 . . . . 0.0 109.186 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 40' ' ' LEU . . . . . 0.614 ' HG ' ' O ' ' C' ' 36' ' ' LEU . 68.2 mt -55.28 -36.99 66.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.6 m95 -64.84 -44.67 89.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.611 -1.305 . . . . 0.0 109.741 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 42' ' ' ILE . . . . . . . . . . . . . 44.6 mt -58.48 -39.72 76.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.696 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.535 ' CD1' HG12 ' A' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 27' ' ' VAL . . . . . 0.543 HG12 ' CD1' ' C' ' 26' ' ' LEU . 91.6 t -65.49 -40.13 87.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.034 -1.041 . . . . 0.0 109.631 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 28' ' ' VAL . . . . . 0.403 ' O ' ' OG ' ' D' ' 31' ' ' SER . 66.1 t -64.77 -46.51 91.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.416 -0.803 . . . . 0.0 108.949 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.22 -49.79 63.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.824 . . . . 0.0 109.832 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.074 -1.016 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 31' ' ' SER . . . . . 0.546 ' O ' HG13 ' D' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.645 ' O ' ' HB3' ' D' ' 37' ' ' HIS . 65.1 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 34' ' ' GLY . . . . . 0.91 ' O ' ' HG ' ' D' ' 38' ' ' LEU . . . -63.07 -42.52 99.56 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 35' ' ' ILE . . . . . 0.546 HG13 ' O ' ' D' ' 31' ' ' SER . 70.6 mt -62.94 -63.66 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.082 -1.246 . . . . 0.0 109.556 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 36' ' ' LEU . . . . . 0.617 ' O ' ' HG ' ' D' ' 40' ' ' LEU . 47.0 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.645 ' HB3' ' O ' ' D' ' 33' ' ' ILE . 6.9 t-160 -61.5 -41.51 97.4 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.623 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 38' ' ' LEU . . . . . 0.91 ' HG ' ' O ' ' D' ' 34' ' ' GLY . 88.0 mt -68.53 -39.57 81.1 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.018 -1.051 . . . . 0.0 109.912 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.54 -46.81 94.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.497 -0.752 . . . . 0.0 109.186 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 40' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' D' ' 36' ' ' LEU . 68.2 mt -55.28 -36.95 66.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.346 -0.846 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -64.93 -44.59 88.97 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.602 -1.311 . . . . 0.0 109.74 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 42' ' ' ILE . . . . . 0.421 ' H ' HG13 ' D' ' 42' ' ' ILE . 44.0 mt -58.51 -39.71 76.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.037 -1.039 . . . . 0.0 109.71 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.526 ' CD1' HG12 ' B' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.535 HG12 ' CD1' ' D' ' 26' ' ' LEU . 91.6 t -65.49 -40.13 87.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.034 -1.041 . . . . 0.0 109.631 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.407 ' O ' ' OG ' ' A' ' 31' ' ' SER . 66.1 t -64.77 -46.51 91.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.416 -0.803 . . . . 0.0 108.949 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.22 -49.79 63.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.824 . . . . 0.0 109.832 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.074 -1.016 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.545 ' O ' HG13 ' A' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.649 ' O ' ' HB3' ' A' ' 37' ' ' HIS . 65.1 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.904 ' O ' ' HG ' ' A' ' 38' ' ' LEU . . . -63.07 -42.55 99.55 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.545 HG13 ' O ' ' A' ' 31' ' ' SER . 70.6 mt -62.88 -63.69 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.091 -1.24 . . . . 0.0 109.567 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.62 ' O ' ' HG ' ' A' ' 40' ' ' LEU . 47.0 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.649 ' HB3' ' O ' ' A' ' 33' ' ' ILE . 6.9 t-160 -61.5 -41.51 97.4 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.623 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.904 ' HG ' ' O ' ' A' ' 34' ' ' GLY . 88.0 mt -68.53 -39.57 81.1 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.018 -1.051 . . . . 0.0 109.912 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.54 -46.81 94.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.497 -0.752 . . . . 0.0 109.186 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.62 ' HG ' ' O ' ' A' ' 36' ' ' LEU . 68.2 mt -55.28 -36.95 66.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.346 -0.846 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -64.93 -44.59 88.97 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.602 -1.311 . . . . 0.0 109.74 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.411 ' H ' HG13 ' A' ' 42' ' ' ILE . 44.3 mt -58.51 -39.71 76.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.037 -1.039 . . . . 0.0 109.71 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.542 ' CD1' HG12 ' C' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.526 HG12 ' CD1' ' A' ' 26' ' ' LEU . 91.6 t -65.49 -40.12 87.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.002 -1.061 . . . . 0.0 109.634 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 66.5 t -64.77 -46.51 91.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.416 -0.803 . . . . 0.0 108.949 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.22 -49.79 63.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.824 . . . . 0.0 109.832 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.074 -1.016 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . 0.554 ' O ' HG13 ' B' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . 0.648 ' O ' ' HB3' ' B' ' 37' ' ' HIS . 65.1 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . 0.91 ' O ' ' HG ' ' B' ' 38' ' ' LEU . . . -63.07 -42.52 99.56 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.554 HG13 ' O ' ' B' ' 31' ' ' SER . 70.7 mt -62.94 -63.66 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.082 -1.246 . . . . 0.0 109.556 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.626 ' O ' ' HG ' ' B' ' 40' ' ' LEU . 47.0 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.648 ' HB3' ' O ' ' B' ' 33' ' ' ILE . 6.9 t-160 -61.48 -41.5 97.36 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.228 -0.92 . . . . 0.0 109.683 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' LEU . . . . . 0.91 ' HG ' ' O ' ' B' ' 34' ' ' GLY . 87.9 mt -68.49 -39.66 81.21 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.018 -1.051 . . . . 0.0 109.895 -179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 95.2 mt -60.47 -46.84 94.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.43 -0.794 . . . . 0.0 109.21 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' LEU . . . . . 0.626 ' HG ' ' O ' ' B' ' 36' ' ' LEU . 68.2 mt -55.28 -36.95 66.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.346 -0.846 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -64.93 -44.59 88.97 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.602 -1.311 . . . . 0.0 109.74 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' ILE . . . . . . . . . . . . . 44.0 mt -58.51 -39.71 76.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.037 -1.039 . . . . 0.0 109.71 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.543 ' CD1' HG12 ' D' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . 0.542 HG12 ' CD1' ' B' ' 26' ' ' LEU . 91.6 t -65.45 -40.13 87.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.034 -1.041 . . . . 0.0 109.619 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . 0.416 ' O ' ' OG ' ' C' ' 31' ' ' SER . 66.5 t -64.71 -46.58 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.49 -0.756 . . . . 0.0 108.981 -179.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.21 -49.77 63.33 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.385 -0.822 . . . . 0.0 109.856 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.09 -1.007 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . 0.543 ' O ' HG13 ' C' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . 0.645 ' O ' ' HB3' ' C' ' 37' ' ' HIS . 65.0 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.923 ' O ' ' HG ' ' C' ' 38' ' ' LEU . . . -63.05 -42.5 99.58 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . 0.543 HG13 ' O ' ' C' ' 31' ' ' SER . 70.7 mt -62.94 -63.66 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.082 -1.246 . . . . 0.0 109.556 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . 0.614 ' O ' ' HG ' ' C' ' 40' ' ' LEU . 46.9 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.645 ' HB3' ' O ' ' C' ' 33' ' ' ILE . 6.9 t-160 -61.5 -41.51 97.4 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.623 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' LEU . . . . . 0.923 ' HG ' ' O ' ' C' ' 34' ' ' GLY . 88.0 mt -68.53 -39.57 81.1 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.018 -1.051 . . . . 0.0 109.912 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.54 -46.81 94.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.453 -0.779 . . . . 0.0 109.186 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' LEU . . . . . 0.614 ' HG ' ' O ' ' C' ' 36' ' ' LEU . 68.2 mt -55.28 -36.99 66.73 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.307 -0.871 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.6 m95 -64.84 -44.67 89.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.611 -1.305 . . . . 0.0 109.741 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 42' ' ' ILE . . . . . . . . . . . . . 44.6 mt -58.48 -39.72 76.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.078 -1.014 . . . . 0.0 109.696 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.535 ' CD1' HG12 ' A' ' 27' ' ' VAL . 66.7 mt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.041 -0.726 . . . . 0.0 109.041 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . 0.543 HG12 ' CD1' ' C' ' 26' ' ' LEU . 91.6 t -65.49 -40.13 87.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.034 -1.041 . . . . 0.0 109.631 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . 0.403 ' O ' ' OG ' ' D' ' 31' ' ' SER . 66.1 t -64.77 -46.51 91.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.416 -0.803 . . . . 0.0 108.949 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.22 -49.79 63.16 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.381 -0.824 . . . . 0.0 109.832 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.78 -36.38 72.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.074 -1.016 . . . . 0.0 109.193 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . 0.546 ' O ' HG13 ' D' ' 35' ' ' ILE . 97.1 p -65.5 -42.19 92.41 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.316 -0.865 . . . . 0.0 109.568 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 73.1 mt -68.71 -50.2 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.282 -0.886 . . . . 0.0 109.463 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.645 ' O ' ' HB3' ' D' ' 37' ' ' HIS . 65.1 mt -65.7 -41.71 91.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.262 -0.899 . . . . 0.0 109.939 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . 0.91 ' O ' ' HG ' ' D' ' 38' ' ' LEU . . . -63.07 -42.52 99.56 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . 0.546 HG13 ' O ' ' D' ' 31' ' ' SER . 70.6 mt -62.94 -63.66 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.082 -1.246 . . . . 0.0 109.556 179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . 0.617 ' O ' ' HG ' ' D' ' 40' ' ' LEU . 47.0 mt -60.54 -40.32 91.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.302 -0.874 . . . . 0.0 109.617 -179.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.645 ' HB3' ' O ' ' D' ' 33' ' ' ILE . 6.9 t-160 -61.5 -41.51 97.4 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.228 -0.92 . . . . 0.0 109.623 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' LEU . . . . . 0.91 ' HG ' ' O ' ' D' ' 34' ' ' GLY . 88.0 mt -68.53 -39.57 81.1 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.018 -1.051 . . . . 0.0 109.912 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 95.1 mt -60.54 -46.81 94.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.497 -0.752 . . . . 0.0 109.186 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' D' ' 36' ' ' LEU . 68.2 mt -55.28 -36.95 66.68 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.346 -0.846 . . . . 0.0 110.597 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 8.5 m95 -64.93 -44.59 88.97 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.602 -1.311 . . . . 0.0 109.74 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 42' ' ' ILE . . . . . 0.421 ' H ' HG13 ' D' ' 42' ' ' ILE . 44.0 mt -58.51 -39.71 76.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.037 -1.039 . . . . 0.0 109.71 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 43' ' ' LEU . . . . . . . . . . . . . 34.3 mt . . . . . 0 N--CA 1.49 1.556 0 O-C-N 121.254 -0.904 . . . . 0.0 109.725 -179.808 . . . . . . . . 0 0 . 1 stop_ save_